PHAT STOCK ANALYSIS

Phathom Pharmaceuticals Inc — price, returns and risk statistics

PHATPhathom Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Price summary

Last Close

11.20 $

Jul 2, 26

Market Cap

919 M $

Q1 2026 (TTM)

52-Week Range

7.83 $18.08 $

Return and risk cards

Total Return

%+25.7

Trailing 1-year performance

Volatility

%61.0

Price fluctuation measure

Sharpe Ratio

0.03

Risk/Return ratio

Sortino Ratio

0.03

Downside risk/return

Distance to Peak

%-38.1

Difference from 52-week peak

Maximum Drawdown

-%48.9

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+16.1%

3M

-1.2%

6M

-32.5%

YTD

-32.5%

1Y

+25.7%

3Y

-15.9%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
PHAT-32.5%Gold-3.8%Silver-11.3%S&P 500+9.3%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current Phathom Pharmaceuticals Inc (PHAT) stock price?

PHAT last closed at 11.20 $ (Jul 2, 26). Price data is refreshed after every trading day.

What is the market capitalization of Phathom Pharmaceuticals Inc?

Phathom Pharmaceuticals Inc (PHAT) has a market capitalization of approximately 919 M $ as of the latest reported period.

Who are the main competitors of PHAT?

Key peers of Phathom Pharmaceuticals Inc include Mesoblast Ltd, TELIX Pharmaceuticals Ltd, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S., CSL Ltd. A detailed metric comparison is available on the Peers tab.

Go deeper on PHAT

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.